Q3 2020 OPKO Health Inc Earnings Call

looking statements to reflect

Events or circumstances after the date of this call before we begin. Let me review the format of today's call. Dr. Phillip Frost chairman and chief executive officer dead. We'll open the call then Steve Ruben up goes Executive Vice President will provide a business update and pipeline review, and then dr. John Cohen will discuss bio-reference Laboratories after that Adam logo will review the company's third-quarter Financial results, and then we'll open the call to questions. Now, let me turn the call over to Dave Frost. Good afternoon and thank you for joining the call today. We're pleased to announce our second consecutive quarter of growth and profitability.

And gain weight by the outstanding performance in our reference Laboratories.

The man for COVID-19 testing has remained strong and the team is focused on providing testing services with efficient turnaround times due in part to their outstanding service off. Our reference has been to provider of choice for the numerous States cities Health Care organizations, professional sports, organizations schools should go pharmacy chains and drive-thru testing sites.

We're also pleased by recovering trying to buy references testing business. Although still be well-planned demek levels were hopeful that the laboratory will return Thursday closes Levels by the end of the year as more people return to Physicians of begin to schedule elective medical procedures. In addition. We're seeing progress with our references new business name Everts, which are partially offset declines to remain a driver of growth on the pharmaceutical side. We continue to make progress along with Pfizer. I recently announced positive results from the phase 3 cross-over study for a symmetric gun which demonstrated as significant decrease in the Life interference total score after twelve weeks of treatment compared to once-daily genotropin.

We're pleased that visor remains on schedule to make us regulatory submissions for marketing approval of symmetric on in the Europe and Japan as for reality impacted by the Democrats has like behind frequently does expectations on the international front. However, our partner V4 has not received marketing approvals and numerous European countries and is on a in a position to launch commercial activities next year.

We initiated our clinical trial for reality to treat patients with COVID-19 in an outpatient setting and hope to have top-line results during the fourth quarter.

There was a strong scientific rationale for royalties role in the anti-infective therapy. And if our trial is successful we expected to make an important contribution to deal with the current Trend demek before I turn the call over to Steve. I'd like to emphasize that we are always considering the best strategies to maximize shareholder value all of our directors and management and many of our employees or shareholders of optical.

it goes with

I was saying that our Focus remains on increasing the value of our shares.

I'll turn the call over to Steve at this time.

Thank you feel good afternoon everyone and thank you for joining us. Today. We are pleased with opcodes advancements across all our business units despite the puts and takes of COVID-19 on the company that's real mentioned by a reference Laboratories continues to be a leading provider of COVID-19 PCR testing services this heightened visibility and the new customer is established during the pandemic have had two additional business relationships with the labs core Services, which we expect will progress. Well beyond the end of the pandemic while the laboratory business is experiencing strong growth a pharmaceutical business continued to advance while continue with the challenges stemming from the pandemic that are impacted so much of the healthcare industry.

Earlier this month in conjunction with Pfizer. We announced positive Sumit raghav phase three top 5 results of a crossover pediatric study the crossover study evaluation so much Rogan administered once-weekly two children three to under 18 years of age with growth hormone deficiency previously treated with daily growth hormone therapy the primary outcome be an improved treatment burden compared to genotropin for injection as measured by the mean overall life experience total score after twelve weeks of treatment in addition to the secondary endpoints showed an overall benefit and treatment experience with the summit Rogan once weekly dosing regimen compared to to the genotropin at 1 daily dosing regimen fiber remains on schedule with respect as regulatory submissions for marketing approval of summer program for children with growth hormone deficiency in the United States, Europe and Japan.

we also presented an update at a recent pituitary Society Workshop entitled update on Summit organ development for the treatment of growth hormone deficiency in pediatric and adult patients often results from each of the phase 3 clinical studies evaluating so much arguing for the treatment of growth hormone deficiency in adults and pediatric patients that presentations available on our website under the subheading news and media announcements now, I'd like to turn to our commercial